Table 2.
Clinical and biochemical characteristics in FCHL subjects and normolipemic controls.
| FCHL subjects n = 162 | Normolipemic controls n = 165 | p | |
|---|---|---|---|
| Men, n (%) | 98 (60.5) | 78 (47.3) | 0.022 |
| Age (years) | 50.4 ± 11.4 | 38.5 ± 14.7 | < 0.001 |
| Body Mass Index (kg/m2) | 25.6 (24.2–26.5) | 23.6 (21.4–26.6) | < 0.001 |
| Total Cholesterol (mg/dL) | 312 ± 36.1 | 170 ± 21.0 | < 0.001 |
| Triglycerides (mg/dL) | 277 (232–373) | 64.0 (49.0–93.0) | < 0.001 |
| LDL cholesterol (mg/dL) | 204 (183–230) | 108 (91.8–117) | < 0.001 |
| HDL cholesterol (mg/dL) | 48.5 ± 12.0 | 55.7 ± 11.4 | 0.015 |
| Apolipoprotein A1 (mg/dL) | 147 ± 25.0 | 147 ± 27.4 | 0.930 |
| Apolipoprotein B (mg/dL) | 167 (165–190) | 83.0 (72.0–91.0 | < 0.001 |
| Lipoprotein(a), (mg/dL) | 39.1 (10.3–80.8) | 16.2 (7.79–44.5) | 0.003 |
| Glucose (mg/dL) | 93.0 (86.0–103) | 85.0 (80.0–92.0) | < 0.001 |
| HbA1c (%) | 5.50 (5.30–5.80) | 5.20 (5.00–5.40) | < 0.001 |
| Type 2 diabetes, n (%) | 13 (8.02) | 2 (1.21) | 0.009 |
| Hypertension, n (%) | 30 (18.5) | 10 (6.06) | 0.001 |
| Cardiovascular disease, n (%) | 7 (4.32) | 0 | 0.016 |
| Tobacco, n (%) | |||
| Non smoker | 51 (31.5) | 96 (58.1) | < 0.001 |
| Smoker | 70 (43.2) | 31 (18.8) | |
| Former smoker | 40 (24.7) | 28 (16.7) | |
| Apolipoprotein E genotype, n (%) | |||
| E3/3 | 113 (69.8) | 109 (66.1) | 0.035 |
| E3/2 | 9 (5.56) | 25 (15.2) | |
| E2/2 | 0 | 0 | |
| E3/4 | 31 (19.1) | 25 (15.2) | |
| E4/4 | 6 (3.70) | 2 (1.21) | |
| E2/4 | 3 | 4 | |
Quantitative continuous variables are expressed as mean ± standard deviation or median [percentile 25–75]. Student’s t or Mann–Whitney tests were used to assess differences between two groups. Quantitative categorical variables are expressed as n (%) and statistical differences were assessed by Chi-squared.